Progression of type 1 diabetes is associated with high levels of soluble PD-1 in islet autoantibody-positive children.
Islet autoantibodies
Prediction of type 1 diabetes
Soluble PD-1
Soluble immune checkpoint molecules
Type 1 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
17
10
2023
accepted:
27
11
2023
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
Type 1 diabetes is an autoimmune disorder that is characterised by destruction of pancreatic beta cells by autoreactive T lymphocytes. Although islet autoantibodies (AAb) are an indicator of disease progression, specific immune biomarkers that can be used as target molecules to halt development of type 1 diabetes have not been discovered. Soluble immune checkpoint molecules (sICM) play a pivotal role in counteracting excessive lymphocyte responses, but their role in type 1 diabetes is unexplored. In this longitudinal study, we measured sICM levels in AAb-positive (AAb We measured the levels of 14 sICM in the sera of AAb We found that AAb This study reveals an sICM profile that is dysregulated during the preclinical stage of type 1 diabetes, and identifies sPD-1 as a pathophysiologically-relevant molecule that is associated with disease progression, offering a potential target for early interventions in autoimmune diabetes.
Identifiants
pubmed: 38214712
doi: 10.1007/s00125-023-06075-3
pii: 10.1007/s00125-023-06075-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero dell'Università e della Ricerca
ID : PE00000007
Organisme : Ministero dell'Università e della Ricerca
ID : 2017 K55HLC 001
Organisme : Ministero dell'Università e della Ricerca
ID : 202077EYN7
Organisme : Ministero dell'Università e della Ricerca
ID : PE00000006
Organisme : Swedish Council for Working Life and Social Research
ID : FAS2004-1775
Organisme : Swedish Council for Working Life and Social Research
ID : FAS2004-177
Organisme : Horizon Europe Program of the European Union
ID : 101094099
Organisme : European Foundation for the Study of Diabetes
ID : European Foundation for the Study of Diabetes/Novo
Organisme : Swedish Research Council
ID : K2005-72X-11242-11A
Organisme : Swedish Research Council
ID : K2008-69X-20826-01-4
Organisme : Fondazione Italiana Sclerosi Multipla
ID : 2018/S/5
Organisme : Fondazione Italiana Sclerosi Multipla
ID : 2020/R/13
Organisme : JDRF Wallenberg Foundation
ID : K 98-99D-12813-01
Informations de copyright
© 2024. The Author(s).
Références
Atkinson MA (2012) The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med 2(11):a007641. https://doi.org/10.1101/cshperspect.a007641
doi: 10.1101/cshperspect.a007641
pubmed: 23125199
pmcid: 3543105
Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38(10):1964–1974. https://doi.org/10.2337/dc15-1419
doi: 10.2337/dc15-1419
pubmed: 26404926
pmcid: 5321245
Vehik K, Lynch KF, Schatz DA et al (2016) Reversion of beta-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care 39(9):1535–1542. https://doi.org/10.2337/dc16-0181
doi: 10.2337/dc16-0181
pubmed: 27311490
pmcid: 5001144
Barker JM, Barriga KJ, Yu L et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89(8):3896–3902. https://doi.org/10.1210/jc.2003-031887
doi: 10.1210/jc.2003-031887
pubmed: 15292324
Kimpimaki T, Kulmala P, Savola K et al (2002) Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 87(10):4572–4579. https://doi.org/10.1210/jc.2002-020018
doi: 10.1210/jc.2002-020018
pubmed: 12364437
Achenbach P, Bonifacio E, Koczwara K, Ziegler AG (2005) Natural history of type 1 diabetes. Diabetes 54(Suppl 2):S25–S31. https://doi.org/10.2337/diabetes.54.suppl_2.s25
doi: 10.2337/diabetes.54.suppl_2.s25
pubmed: 16306336
De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P (2018) Not all immune checkpoints are created equal. Front Immunol 9:1909. https://doi.org/10.3389/fimmu.2018.01909
doi: 10.3389/fimmu.2018.01909
pubmed: 30233564
pmcid: 6127213
Gu D, Ao X, Yang Y, Chen Z, Xu X (2018) Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer 6(1):132. https://doi.org/10.1186/s40425-018-0449-0
doi: 10.1186/s40425-018-0449-0
pubmed: 30482248
pmcid: 6260693
Itoh A, Ortiz L, Kachapati K et al (2019) Soluble CD137 ameliorates acute type 1 diabetes by inducing T cell anergy. Front Immunol 10:2566. https://doi.org/10.3389/fimmu.2019.02566
doi: 10.3389/fimmu.2019.02566
pubmed: 31787971
pmcid: 6853870
Gerold KD, Zheng P, Rainbow DB, Zernecke A, Wicker LS, Kissler S (2011) The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 60(7):1955–1963. https://doi.org/10.2337/db11-0130
doi: 10.2337/db11-0130
pubmed: 21602513
pmcid: 3121435
Bruzzaniti S, Piemonte E, Mozzillo E et al (2022) High levels of blood circulating immune checkpoint molecules in children with new-onset type 1 diabetes are associated with the risk of developing an additional autoimmune disease. Diabetologia 65(8):1390–1397. https://doi.org/10.1007/s00125-022-05724-3
doi: 10.1007/s00125-022-05724-3
pubmed: 35610521
Ludvigsson J, Ludvigsson M, Sepa A (2001) Screening for prediabetes in the general child population: maternal attitude to participation. Pediatr Diabetes 2(4):170–174. https://doi.org/10.1034/j.1399-5448.2001.20405.x
doi: 10.1034/j.1399-5448.2001.20405.x
pubmed: 15016182
Nygren M, Carstensen J, Koch F, Ludvigsson J, Frostell A (2015) Experience of a serious life event increases the risk for childhood type 1 diabetes: the ABIS population-based prospective cohort study. Diabetologia 58(6):1188–1197. https://doi.org/10.1007/s00125-015-3555-2
doi: 10.1007/s00125-015-3555-2
pubmed: 25870022
Terrazzano G, Bruzzaniti S, Rubino V et al (2020) T1D progression is associated with loss of CD3
doi: 10.1038/s42255-020-0173-1
American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69. https://doi.org/10.2337/dc10-S062
doi: 10.2337/dc10-S062
pmcid: 2797383
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125(1–2):279–284. https://doi.org/10.1016/s0166-4328(01)00297-2
doi: 10.1016/s0166-4328(01)00297-2
pubmed: 11682119
So M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C (2020) Autoantibody reversion: changing risk categories in multiple-autoantibody-positive individuals. Diabetes Care 43(4):913–917. https://doi.org/10.2337/dc19-1731
doi: 10.2337/dc19-1731
pubmed: 32019856
pmcid: 7085807
Pugliese A (2017) Autoreactive T cells in type 1 diabetes. J Clin Invest 127(8):2881–2891. https://doi.org/10.1172/JCI94549
doi: 10.1172/JCI94549
pubmed: 28762987
pmcid: 5531393
Liu C, Jiang J, Gao L et al (2015) Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther 17:340. https://doi.org/10.1186/s13075-015-0859-z
doi: 10.1186/s13075-015-0859-z
pubmed: 26608464
pmcid: 4659197
Du Y, Nie L, Xu L, Wu X, Zhang S, Xue J (2020) Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: association with activity and severity. Scand J Immunol 92(1):e12884. https://doi.org/10.1111/sji.12884
doi: 10.1111/sji.12884
pubmed: 32243638